GERN Market Cap History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Also see: GERN Shares Outstanding History and GERN YTD Return |
GERN Market Cap History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Also see: GERN Shares Outstanding History and GERN YTD Return |
GERN Market Cap History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
+10.95% CAGR ![]() Mouse over chart for data details
|
GERN Stock Price Chart |
About Geron Corp. |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. Co. is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. We show 59 historical shares outstanding datapoints in our GERN shares outstanding history coverage, used to compute GERN market cap on those dates. Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing GERN market cap history over the course of time is important for investors interested in comparing GERN's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of GERN versus a peer is one thing; comparing GERN market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like GERN can fluctuate over the course of history. With this page we aim to empower investors researching GERN by allowing them to research the GERN market cap history. |
GERN Current Stock Quote |
![]() Get Dividend Alerts ![]() Get SEC Filing Alerts ![]() |
Video: The Importance of Market Cap | |
|
GERN Share Performance |
Market Cap Peers |
Geron (GERN) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:
GFOR Market Cap History |
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.3%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.3%.